Two New Appointments at Meditor Pharmaceuticals Ltd.

Tuesday, May 13, 2008 General News J E 4
REHOVOT, Israel, May 12 Meditor Pharmaceuticals Ltd.announced today the appointment of Prof. Arie Schachner to serve as a SeniorMedical Advisor to the company.

Dr. Schachner has been a member of Meditor's Scientific Advisory Boardsince 2001 and will now take a more active role in the Clinical Developmentprogram.

Prof. Schachner was the founder and Head of the Cardiac Surgery Departmentat Wolfson Medical Center and Tel Aviv University Sackler Medical School. Heis an opinion leader in the Cardiac Surgery area, he is a distinguished memberof several professional societies and has many publications in this field.Prof. Schachner will collaborate with recently appointed CEO, Dr. AdrianHarel, in the ongoing Phase II Clinical trial on Hypotension in patientsundergoing Cardio Artery Bypass Graft (CABG) patients and in designing futureclinical trials.

Dr. Adrian Harel joined Meditor in January 2008. He combines a broadscientific education with extensive industry experience. He holds a Ph.D. inNeurobiology, from the Weizmann Institute of Science, and was a postdoctoralat Washington University. Dr. Harel has many years of experience in thepharmaceutical and biotech industry. Dr. Harel has extensive Drug research &development know-how and GMP production and manufacturing knowledge.

About Meditor Pharmaceuticals: Meditor Pharmaceuticals Ltd. is abiopharmaceutical company dedicated to the development and commercializationof proprietary products for the therapeutic management of acute and chronichypotension and hypotension-related disorders. The lead development compoundis a unique low molecular weight S-Alkylisothiouronium derivative thataddresses a variety of acute and chronic therapeutic indications associatedwith hypotension. The clinical development program is focused on thedevelopment of lead compound MTR104 for the treatment of three main medicaltargets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106(immediate release oral tablet formulation) for Migraine, and MTR105 (i.v.formulation) for the treatment of hypotension associated with cardiac surgery.Meditor's patent portfolio provides the company with a strong proprietaryposition in the U.S. and worldwide. For more information on the company andits drug development activities, please visit

For all inquiries please contact Mr. Rafi Barkan, Chairman at +972 8 9303307 or Dr. Adrian Harel, CEO at +972 8 930 3305.

SOURCE Meditor Pharmaceuticals Ltd.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Anadys Pharmaceuticals to Present at Two Upcoming ...
Two New Appointments at Meditor Pharmaceuticals Lt...